Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Praluzatamab Ravtansine · CX-2009

Antibody-drug conjugate · Cytotoxic, directed at CD166 (ALCAM) (ALCAM) · developed by CytomX Therapeutics

Phase 2 Most advanced trial (none active)
CTMX Developer
1 Registered trials

What is Praluzatamab Ravtansine?

Praluzatamab ravtansine (CX-2009) is a probody drug conjugate in which an anti-CD166 antibody, masked by a cleavable peptide, carries the cytotoxic maytansinoid DM4. The masking peptide is cleaved by proteases in the tumor microenvironment, allowing the antibody to bind CD166-expressing tumor cells; released DM4 binds tubulin and disrupts microtubule dynamics. It is studied in breast cancer, including triple-negative and hormone receptor-positive/HER2-negative disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CX-2009
Drug type
Antibody-drug conjugate
Targets
CD166 (ALCAM) (ALCAM), tubulin (secondary target)
Mechanism
Cytotoxic, directed at CD166 (ALCAM) (ALCAM)
Pathways
microtubule assembly/disassembly, cell division inhibition
Therapy area
Oncology
Developer
CytomX Therapeutics (CTMX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
RD2I59M9FC

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04596150 Phase 2 Neoplasms Completed CTMX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Breast CancerBreast NeoplasmsBreast Neoplasms, Hormone Receptor Positive/HER2 NegativeBreast Neoplasms, Triple-NegativeNeoplasms

More from CytomX Therapeutics

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the CTMX page.

Follow CTMX, the company behind Praluzatamab Ravtansine

See CTMX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CTMX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.